Modern chemoradiation and chemotherapy protocols for locally advanced rectal cancer: The current and future standards of care

Amikar Sehdev, Blase Polite

Research output: Contribution to journalArticle

Abstract

The introduction of radiotherapy, chemoradiotherapy, and total mesorectal excision has significantly changed the treatment landscape of locally advanced rectal cancer (LARC) in the last two decades. A number of large randomized controlled trials have established preoperative chemoradiotherapy followed by total mesorectal excision as the standard of care treatment. The addition of oxaliplatin, irinotecan, bevacizumab, or anti-EGFR therapies to 5-fluorouracil or capecitabine and radiation therapy has failed to improve outcomes at an acceptable toxicity. With excellent control of local recurrences (5-10%), the focus has shifted to reducing distant metastases and improving pathological complete response. Despite no proven benefit, adjuvant chemotherapy remains the standard of care in the United States based on extrapolation from colon cancer trials. Defining the best chemotherapy combination has remained a challenge. Trials are ongoing to address the best sequence of the most efficacious combination chemotherapy to be given either before or after preoperative chemoradiotherapy. In this review, we have summarized the literature of LARC and addressed the role and sequence of different chemotherapy combinations with respect to surgery and radiotherapy in the multimodality treatment. Lastly, we discuss important questions that need to be addressed for future clinical trials.

Original languageEnglish (US)
Pages (from-to)132-141
Number of pages10
JournalSeminars in Colon and Rectal Surgery
Volume24
Issue number3
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Standard of Care
Rectal Neoplasms
Chemoradiotherapy
Combination Drug Therapy
Drug Therapy
irinotecan
oxaliplatin
Radiotherapy
Therapeutics
Adjuvant Chemotherapy
Fluorouracil
Colonic Neoplasms
Randomized Controlled Trials
Clinical Trials
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

Cite this

@article{a0776d8734594d899d0cad693d8c142d,
title = "Modern chemoradiation and chemotherapy protocols for locally advanced rectal cancer: The current and future standards of care",
abstract = "The introduction of radiotherapy, chemoradiotherapy, and total mesorectal excision has significantly changed the treatment landscape of locally advanced rectal cancer (LARC) in the last two decades. A number of large randomized controlled trials have established preoperative chemoradiotherapy followed by total mesorectal excision as the standard of care treatment. The addition of oxaliplatin, irinotecan, bevacizumab, or anti-EGFR therapies to 5-fluorouracil or capecitabine and radiation therapy has failed to improve outcomes at an acceptable toxicity. With excellent control of local recurrences (5-10{\%}), the focus has shifted to reducing distant metastases and improving pathological complete response. Despite no proven benefit, adjuvant chemotherapy remains the standard of care in the United States based on extrapolation from colon cancer trials. Defining the best chemotherapy combination has remained a challenge. Trials are ongoing to address the best sequence of the most efficacious combination chemotherapy to be given either before or after preoperative chemoradiotherapy. In this review, we have summarized the literature of LARC and addressed the role and sequence of different chemotherapy combinations with respect to surgery and radiotherapy in the multimodality treatment. Lastly, we discuss important questions that need to be addressed for future clinical trials.",
author = "Amikar Sehdev and Blase Polite",
year = "2013",
month = "9",
doi = "10.1053/j.scrs.2013.03.005",
language = "English (US)",
volume = "24",
pages = "132--141",
journal = "Seminars in Colon and Rectal Surgery",
issn = "1043-1489",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Modern chemoradiation and chemotherapy protocols for locally advanced rectal cancer

T2 - The current and future standards of care

AU - Sehdev, Amikar

AU - Polite, Blase

PY - 2013/9

Y1 - 2013/9

N2 - The introduction of radiotherapy, chemoradiotherapy, and total mesorectal excision has significantly changed the treatment landscape of locally advanced rectal cancer (LARC) in the last two decades. A number of large randomized controlled trials have established preoperative chemoradiotherapy followed by total mesorectal excision as the standard of care treatment. The addition of oxaliplatin, irinotecan, bevacizumab, or anti-EGFR therapies to 5-fluorouracil or capecitabine and radiation therapy has failed to improve outcomes at an acceptable toxicity. With excellent control of local recurrences (5-10%), the focus has shifted to reducing distant metastases and improving pathological complete response. Despite no proven benefit, adjuvant chemotherapy remains the standard of care in the United States based on extrapolation from colon cancer trials. Defining the best chemotherapy combination has remained a challenge. Trials are ongoing to address the best sequence of the most efficacious combination chemotherapy to be given either before or after preoperative chemoradiotherapy. In this review, we have summarized the literature of LARC and addressed the role and sequence of different chemotherapy combinations with respect to surgery and radiotherapy in the multimodality treatment. Lastly, we discuss important questions that need to be addressed for future clinical trials.

AB - The introduction of radiotherapy, chemoradiotherapy, and total mesorectal excision has significantly changed the treatment landscape of locally advanced rectal cancer (LARC) in the last two decades. A number of large randomized controlled trials have established preoperative chemoradiotherapy followed by total mesorectal excision as the standard of care treatment. The addition of oxaliplatin, irinotecan, bevacizumab, or anti-EGFR therapies to 5-fluorouracil or capecitabine and radiation therapy has failed to improve outcomes at an acceptable toxicity. With excellent control of local recurrences (5-10%), the focus has shifted to reducing distant metastases and improving pathological complete response. Despite no proven benefit, adjuvant chemotherapy remains the standard of care in the United States based on extrapolation from colon cancer trials. Defining the best chemotherapy combination has remained a challenge. Trials are ongoing to address the best sequence of the most efficacious combination chemotherapy to be given either before or after preoperative chemoradiotherapy. In this review, we have summarized the literature of LARC and addressed the role and sequence of different chemotherapy combinations with respect to surgery and radiotherapy in the multimodality treatment. Lastly, we discuss important questions that need to be addressed for future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84882969187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882969187&partnerID=8YFLogxK

U2 - 10.1053/j.scrs.2013.03.005

DO - 10.1053/j.scrs.2013.03.005

M3 - Article

AN - SCOPUS:84882969187

VL - 24

SP - 132

EP - 141

JO - Seminars in Colon and Rectal Surgery

JF - Seminars in Colon and Rectal Surgery

SN - 1043-1489

IS - 3

ER -